Price
CHART BY
Frequently asked questions
What is Mersana's market capitalization?
The market capitalization of Mersana is $36.27M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Mersana?
Mersana's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.60. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Mersana's stock?
Currently, 7 analysts cover Mersana's stock, with a consensus target price of $4.50. Analyst ratings provide insights into the stock's expected performance.
What is Mersana's revenue over the trailing twelve months?
Over the trailing twelve months, Mersana reported a revenue of $34.01M.
What is the EBITDA for Mersana?
Mersana's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$75.33M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Mersana?
Mersana has a free cash flow of -$79.01M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Mersana have, and what sector and industry does it belong to?
Mersana employs approximately 102 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Mersana's shares?
The free float of Mersana is 96.84M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $36.27M
- EPS (TTM)
- -$0.60
- Free Float
- 96.84M
- Revenue (TTM)
- $34.01M
- EBITDA (TTM)
- -$75.33M
- Free Cashflow (TTM)
- -$79.01M
Pricing
- 1D span
- $0.295$0.343
- 52W span
- $0.26$2.825
Analyst Ratings
The price target is $4.50 and the stock is covered by 7 analysts.
Buy
6
Hold
1
Sell
0
Information
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
- Employees
- 102
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US59045L1061
- Primary Ticker
- MRSN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet